Brian Hill, MD, PhD, of Cleveland Clinic discusses updates surrounding CLL, specifically responses to Ibrutinib and Venetoclax as the optimal choice of therapy at the 58th ASH Annual Meeting in San Diego, CA.
Venetoclax in 2nd Line after Ibrutinib failure may be more optimal than other treatments
